✦ LIBER ✦

P01.05 Current clinical use of daptomycin in Europe from the European Cubicin® Outcomes Registry and Experience (EU-CORE)

✍ Scribed by A. Gonzalez-Ruiz; P. Gargalianos-Kakolyris; Z. Dailiana; A. Cogo; V.J. González-Ramallo; P. Dohmen; M.C. Fariñas; A. Galloway; P. Nikolaidis; K. Bouylout; J. Loeffler; R.L. Chaves

Book ID: 114182722
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 43 KB
Volume: 76
Category: Article
ISSN: 0195-6701
DOI: 10.1016/s0195-6701(10)60036-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daptomycin for the treatment of enteroco

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)

✍ John F. Mohr; Lawrence V. Friedrich; Sara Yankelev; Kenneth C. Lamp 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 211 KB

Safety of daptomycin in patients complet

Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and Experience

✍ Rege, Shruta; Mohr, John; Lamp, Kenneth C.; Yoon, Min; Lindfield, Kimberly C. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 172 KB